Visualization of Ranger Drug Coated Balloon, from side close-up.
TAKE THE FIGHT TO PAD

Effortless deliverability.
Exceptional outcomes.

 

 

A bold step forward.

Boston Scientific is committed to advancing science in the fight against PAD by boldly innovating with next-generation, drug-eluting technology. Backed by Level-1 Randomized Controlled Trials, our exceptional results put the power of choice in the hands of those who make it happen. Together, we can save more limbs and help more people walk without pain.

 

Ranger Drug Eluted Stent illustration with purple tip

NEXT-GENERATION TECHNOLOGY

Delivers like nothing else.

Ranger DCB is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform1 with the lowest tip entry profile of any SFA DCB2. For ease, durability and effectiveness, Ranger DCB delivers like nothing else.
Man sitting on porch with cane at his side, looking to the right.

BOLD CLINICAL TRIALS

Two Randomized Controlled DCB Trials.
Zero doubt.

Bold is being the first company to voluntarily evaluate our Drug-Coated Balloon against another DCB in a Level-1 Randomized Controlled Trial for comparative effectiveness. Ranger™ DCB demonstrated similar primary patency as IN.PACT with half the total drug dose3 at 2-Years. And consistently demonstrated high primary patency, near 90%, at 1-Year in the RANGER II SFA & COMPARE Trials4.

 

Clinical Highlights

 

Exceptional outcomes at 2-Years. No matter the lesion complexity. No matter the patient.5

In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency
at 2-Years.5

Ranger DCB primary patency chart
*Log-rank p-value compares the entire K-M curves from time zero to day 760 (full 2-Year follow-up-window)
1. DRG Data, CY 2020, 0.018" PTA Balloons
2.Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™  035 DCB, IN.PACT Admiral DCB and Stellarex™  035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
3. COMPARE Clinical Trial 2-Year Results presented by Sabine Steiner, MD. LINC 2021. Based on total drug dose for (4mmx60mm) or (average for full size matrix) per Ranger™ Paclitaxel-Coated PTA Balloon Catheter and IN.PACT™ Admiral Instructions for Use.
4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.
5. RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD. VIVA 2021.
  
Legs and feet of patient sitting on bed with hands on lap.

RESTENOSIS REPLACEMENT PROGRAM

Standing together.

The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis. 
Background image of surgical area and healthcare providers' hands.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

take the fight to pad
Top